I wouldn't expect to see much more than you have historically on this board. There are two schools of thought -- one that thinks the stock is cheap on the basis of dividend yield and PE, the other that thinks the stock is overvalued, since the company's principal source of revenue and cash flow is going away in 7 quarters and their current investments cannot come close to making up the difference. I happen to be in the latter camp. The proof will be in the pudding and will play out over the next year or so.
Read n article from Seeking Alpha, the author stated that the Annual Quarter report will report about .46 eps a 25% decline since last year. Even though monoclonal is a new invention which is used in combination for chemo, rheumatoid arthritis. PDLI would need to to invest in other inventions to expand and not just one intended invention and riding with it.